Evidence types
Case report articles covering individual patient cases, unusual presentations, rare complications, or early clinical observations in IBD. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
20 articles
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical journal...
Based on the title and source metadata, this appears to be a case report related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of the Formosan Medical Association =...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
The report highlights a serious drug-related complication (pancytopenia/myelosuppression and hair loss) in a patient treated with azathioprine plus sulfasalazine for ulcerative colitis, suggesting clinicians and patients...
The case links thymic hyperplasia, thyroid autoimmunity, and severe UC with colorectal neoplasia, suggesting possible shared immune dysregulation that might interest patients and clinicians, but it does not support...
Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...
PG is a serious skin complication that can occur with UC. This report suggests guselkumab—an IL‑23 blocker used in IBD and dermatology—helped resolve PG in one patient without loss of UC remission, which could be...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Immunity, inflammation...
A new IL-17A drug (vunakizumab) is reported to have triggered severe ulcerative colitis in one patient, suggesting clinicians and patients starting IL-17A inhibitors should watch for early gastrointestinal symptoms.
A JAK inhibitor (upadacitinib) used for moderate–severe ulcerative colitis can cause neutropenia; this case report discusses how it was identified and managed, which matters for patients on the drug and clinicians...
Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...
Because intestinal lymphoma can closely mimic Crohn’s disease, recognizing red flags (severe malabsorption, proximal small-bowel involvement, monoclonal gammopathy, poor response to IBD therapy) can change diagnosis and...
The video demonstrates a bowel-preserving robotic surgical technique for ileal strictures in Crohn's disease that could help surgeons perform technically demanding intracorporeal suturing and preserve bowel length.
This small case series suggests upadacitinib may induce and maintain steroid-free remission in some UC patients after tofacitinib failure, a potential option for people with refractory disease.
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
The coexistence of Peutz-Jeghers syndrome and Crohn's disease is exceptionally rare, and both conditions carry increased cancer risk. Patients, families, and clinicians need to know that there is little evidence to guide...
LCH can present like perianal Crohn's disease and may be missed if biopsies and molecular testing are not performed. Correct diagnosis changes treatment and prompts systemic staging for other malignancies.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from cureus.com.
